Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00038675 · BASELINE

Baseline characteristics

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate · Source last updated 2022-01-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      125
    units
    Participants
groups
  1. description
    Imatinib mesylate 400 mg orally daily, HES participants start with 100 mg orally daily.
    id
    BG000
    title
    Imatinib Mesylate
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          21
          upper Limit
          84
          value
          56
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          49
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          76
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          125
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          10
      title
      Acute Leukemia
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          7
      title
      Chronic myeloproliferative disorders (CMPD)
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          11
      title
      Chronic Myelomonocytic Leukemia (CMML)
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      Essential Thrombocythemia
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          20
      title
      Hypereosinophilic syndrome (HES)
    6. categories
      1. measurements
        1. group Id
          BG000
          value
          25
      title
      Systemic mastocytosis (SM)
    7. categories
      1. measurements
        1. group Id
          BG000
          value
          7
      title
      Myelodysplastic syndromes (MDS)
    8. categories
      1. measurements
        1. group Id
          BG000
          value
          18
      title
      Myelofibrosis
    9. categories
      1. measurements
        1. group Id
          BG000
          value
          25
      title
      Polycythemia Vera (PV)
    description
    Leukemia diagnosis and any subtype determination confirmed via bone marrow aspirate and/or biopsy, assessed prior to treatment.
    param Type
    NUMBER
    title
    Leukemia Diagnosis Categories
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      125
    units
    Participants
groups
  1. description
    Imatinib mesylate 400 mg orally daily, HES participants start with 100 mg orally daily.
    id
    BG000
    title
    Imatinib Mesylate
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          21
          upper Limit
          84
          value
          56
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          49
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          76
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          125
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          10
      title
      Acute Leukemia
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          7
      title
      Chronic myeloproliferative disorders (CMPD)
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          11
      title
      Chronic Myelomonocytic Leukemia (CMML)
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      Essential Thrombocythemia
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          20
      title
      Hypereosinophilic syndrome (HES)
    6. categories
      1. measurements
        1. group Id
          BG000
          value
          25
      title
      Systemic mastocytosis (SM)
    7. categories
      1. measurements
        1. group Id
          BG000
          value
          7
      title
      Myelodysplastic syndromes (MDS)
    8. categories
      1. measurements
        1. group Id
          BG000
          value
          18
      title
      Myelofibrosis
    9. categories
      1. measurements
        1. group Id
          BG000
          value
          25
      title
      Polycythemia Vera (PV)
    description
    Leukemia diagnosis and any subtype determination confirmed via bone marrow aspirate and/or biopsy, assessed prior to treatment.
    param Type
    NUMBER
    title
    Leukemia Diagnosis Categories
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice